S-Space

Browse

Author

Showing results 1 to 2 of 2

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2021-08	Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival Slamon, D. J.; Neven, P.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S.; Petrakova, K.; Bianchi, G. Valeria; Martin, M.; Nusch, A.; Sonke, G. S.; De la Cruz-Merino, L.; Beck, J. T.; Ji, Y.; Wang, C.; Deore, U.; Chakravartty, A.; Zarate, J. P.; Taran, T.; Fasching, P. A. Annals of Oncology, Vol.32 No.8, pp.1015-1024	DOI
2023-08	Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant Neven, P.; Fasching, P. A.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S.-A.; Petrakova, K.; Bianchi, G. V.; Martín, M.; Nusch, A.; Sonke, G. S.; De la Cruz-Merino, L.; Beck, J. T.; Zarate, J. P.; Wang, Y.; Chakravartty, A.; Wang, C.; Slamon, D. J. Breast Cancer Research, Vol.25(1):103	view file DOI